酒石酸美托洛尔治疗扩张型心肌病的临床疗效及其药理作用分析

Clinical efficacy of metoprolol tartrate in treatment of dilated cardiomyopathy and its pharmacological action

目的:探讨酒石酸美托洛尔治疗扩张型心肌病的临床疗效及其药理作用。方法:选择某院收治的扩张型心肌病患者90例,参照随机数字表法将其分为2组,每组各45例。对照组采用常规治疗,在此基础上给予观察组酒石酸美托洛尔治疗,比较2组临床疗效、心功能及心血管不良事件发生率。结果:观察组治疗总有效率较对照组高,2组比较差异有统计学意义(P<0.05);治疗后,2组各项心功能指标均明显改善,且观察组LVESd较对照组高,LVEF,LVEDd及心率均较对照组低,差异有统计学意义(P<0.05);心血管不良事件总发生率观察组较对照组低,差异有统计学意义(P<0.05)。结论:酒石酸美托洛尔可提高扩张型心肌病患者临床疗效,减轻心肌损伤,改善心功能,降低心血管不良事件发生率。

Objective ：To analyze the clinical efficacy of metoprolol tartrate in treatment of dilated cardiomyopathy （DCM） and its phannacological action. Methods ：90 DCM patients in a hospital were selected and randomly divided into two groups, 45 cases in each. The control group was given routine treatment,while the observation group was treated with metoprolol tartrate based on the therapy of the control group. Clinical efficacy, cardiac traction and incidence of adverse cardiovascular events were compared between the two groups. Results ：The total effective rate of the observation group was higher than that of the control group （ P 〈 0.05 ）. After the treatment, the indexes of cardiac traction in the two groups significantly improved. LVESd in the observation group was higher than that in the control group, while LVEF, LVEDd and heart rate were lower than the control group （ P 〈 0.05 ）. The total incidence of adverse cardiovascular events in the observation group was lower than that in the control group （ P 〈 0.05 ）. Conclusion ： Metoprolol tartrate in treatment of DCM can increase clinical efficacy, reduce myocardial injury, improve cardiac function and decrease the incidence of adverse cardiovascular events.